🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

All human beings are born free and equal in dignity and rights. Every human has a right to health! #HealthForAll #PrideMonth

Lesbian rights are human rights. Gay rights are human rights. Bisexual rights are human rights. Transgender rights are human rights. Happy Pride! 🏳️‍🌈

Those three moments of glory, straight from champion’s heaven.🫶

Wow, right? 7:30 Monday at #ASCO25. Agree! No doubt #DB09 will be practice changing. The question is, how will we handle maintenance?

Particularly excited about the activity in #TNBC post topo-1 ADCs. 86% had seen savituzumab govitecan, 1/3 had seen T-DXd, 1/4 had seen both! #ASCO25 #ADC #NewTargetNewPayload

Happening NOW at #ASCO25 !! Poster presented by Guilherme Nader Marta on long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the #ALTTOtrial ! Go check poster 135! Institut Jules Bordet Instituut Dana-Farber Harvard University

At the MBC poster session at #ASCO25, Elisa Agostinetto presents OS results and ctDNA analyses from the SYNERGY randomized phase 2 academic study sponsored by Institut Jules Bordet Instituut . SYNERGY investigated oleclumab and durvalumab with chemotherapy in the 1st line setting of metastatic TNBC

How does HER2+ ILC fare long-term? #ALTTO data ⬆️ CNS relapse risk in ILC vs NST (13.6% vs 5.0%; HR 3.14) – DFS & OS similar despite clinicopathologic differences – Importance of central histology review Poster BD135 | #ASCO25 – come by! OncoAlert

When I read studies scientifically analyzing pig screams in slaughterhouses, I can't help but wonder what future generations may think when they come across papers like this.

Presenting 2 posters this morning at the ASCO #ASCO25 Breast Cancer poster session — both focused on #ILC. Proud to advance lobular breast cancer research with Lobular Breast Cancer Alliance. Poster #1 (in collaboration with BostonGeneCorp) was selected for a GRASP award! Stop by and say

At #ASCO25 , Michail ignatiadis presented the study design of TREAT ctDNA, an academic randomized trial investigating ctDNA dynamics and the novel oral SERD elacestrant in HR+/HER2- early breast cancer clinicaltrials.gov/study/NCT05512… Institut Jules Bordet Instituut EORTC

Dear Colleagues at #ASCO25 An honor to present Angela Toss Presenting on Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with #BreastCancer Eva Blondeaux Cynthia Villarreal-Garza, MD DSc Carmine De Angelis Elisa Agostinetto Breast Cancer

The medical lead of our early phases clinical trials program at the Institut Jules Bordet Instituut Clinical Trials Conduct Unit Nuria Kotecki, MD is the lead PI for a phase 1/2 study investigating the Salubris Biotherapeutics 5T4 antibody-drug conjugate. She presented the study design at #ASCO25

Take homes from #ASCO25 rechallenge with tdxd after ild can work; sg first line tnbc; vepdeg me too; inavo impressive in endocrine resistant; dose escalation of abema better; tdxd first line her2 but maybe try maintenance hp; ofs for high risk a must; nk3 for hot flashes #bcsm

Another ASCO comes to its end, bringing good memories So grateful that our work was awarded with a Conquer Cancer, the ASCO Foundation Merit Award & a #GRASP patient advocacy award💫 Honored to have been speaker for ASCO TECAG and to share all this with amazing colleagues & friends❤️ OncoAlert

"Fabian a joué, il a perdu", chronique de la haine ordinaire rtbf.be/article/fabian…

On #WorldEnvironmentDay, ESMO stands w/ the global community to #BeatPlasticPollution. #Microplastics are found in organs and tumours. More research needed to understand their role in cancer development Pawel Sobczuk 🔗 ow.ly/Q8xT50W3VCP #ESMODailyReporter

Wild Brussels 💜

"Peut-être est-il grand temps de relever la tête de vos portables, de regarder le monde autour pour réhydrater la part d'humanité qui a séché dans les méandres de vos algorithmes très, très individuels." 👏👏👏 #Fabian rtbf.be/article/mort-d…